Cargando…
Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer
In this study, we collected genes related to energy metabolism, used gene expression data from public databases to classify molecular subtypes of colon cancer (COAD) based on the genes related to energy metabolism, and further evaluated the relationships between the molecular subtypes and prognosis...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251179/ https://www.ncbi.nlm.nih.gov/pubmed/32509568 http://dx.doi.org/10.3389/fonc.2020.00595 |
_version_ | 1783538911268569088 |
---|---|
author | Yuan, Yihang Chen, Ji Wang, Jue Xu, Ming Zhang, Yunpeng Sun, Peng Liang, Leilei |
author_facet | Yuan, Yihang Chen, Ji Wang, Jue Xu, Ming Zhang, Yunpeng Sun, Peng Liang, Leilei |
author_sort | Yuan, Yihang |
collection | PubMed |
description | In this study, we collected genes related to energy metabolism, used gene expression data from public databases to classify molecular subtypes of colon cancer (COAD) based on the genes related to energy metabolism, and further evaluated the relationships between the molecular subtypes and prognosis and clinical characteristics. Differential expression analysis of the molecular subtypes yielded 1948 differentially expressed genes (DEGs), whose functions were closely related to the occurrence and development of cancer. Based on the DEGs, we constructed a 4-gene prognostic risk model and identified the high expression of FOXD4, ENPEP, HOXC6, and ALOX15B as a risk factor associated with a high risk of developing COAD. The 4-gene signature has strong robustness and a stable predictive performance in datasets from different platforms not only in patients with early COAD but also in all patients with colon cancer. The enriched pathways of the 4-gene signature in the high- and low-risk groups obtained by GSEA were significantly related to the occurrence and development of colon cancer. Moreover, the results of qPCR, immunohistochemistry staining and Western blot assay revealed that FOXD4, ENPEP, HOXC6, and ALOX15B are over expressed in CRC tissues and cells. These results suggesting that the signature could potentially be used as a prognostic marker for clinical diagnosis. |
format | Online Article Text |
id | pubmed-7251179 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72511792020-06-05 Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer Yuan, Yihang Chen, Ji Wang, Jue Xu, Ming Zhang, Yunpeng Sun, Peng Liang, Leilei Front Oncol Oncology In this study, we collected genes related to energy metabolism, used gene expression data from public databases to classify molecular subtypes of colon cancer (COAD) based on the genes related to energy metabolism, and further evaluated the relationships between the molecular subtypes and prognosis and clinical characteristics. Differential expression analysis of the molecular subtypes yielded 1948 differentially expressed genes (DEGs), whose functions were closely related to the occurrence and development of cancer. Based on the DEGs, we constructed a 4-gene prognostic risk model and identified the high expression of FOXD4, ENPEP, HOXC6, and ALOX15B as a risk factor associated with a high risk of developing COAD. The 4-gene signature has strong robustness and a stable predictive performance in datasets from different platforms not only in patients with early COAD but also in all patients with colon cancer. The enriched pathways of the 4-gene signature in the high- and low-risk groups obtained by GSEA were significantly related to the occurrence and development of colon cancer. Moreover, the results of qPCR, immunohistochemistry staining and Western blot assay revealed that FOXD4, ENPEP, HOXC6, and ALOX15B are over expressed in CRC tissues and cells. These results suggesting that the signature could potentially be used as a prognostic marker for clinical diagnosis. Frontiers Media S.A. 2020-05-20 /pmc/articles/PMC7251179/ /pubmed/32509568 http://dx.doi.org/10.3389/fonc.2020.00595 Text en Copyright © 2020 Yuan, Chen, Wang, Xu, Zhang, Sun and Liang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yuan, Yihang Chen, Ji Wang, Jue Xu, Ming Zhang, Yunpeng Sun, Peng Liang, Leilei Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer |
title | Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer |
title_full | Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer |
title_fullStr | Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer |
title_full_unstemmed | Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer |
title_short | Development and Clinical Validation of a Novel 4-Gene Prognostic Signature Predicting Survival in Colorectal Cancer |
title_sort | development and clinical validation of a novel 4-gene prognostic signature predicting survival in colorectal cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251179/ https://www.ncbi.nlm.nih.gov/pubmed/32509568 http://dx.doi.org/10.3389/fonc.2020.00595 |
work_keys_str_mv | AT yuanyihang developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer AT chenji developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer AT wangjue developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer AT xuming developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer AT zhangyunpeng developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer AT sunpeng developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer AT liangleilei developmentandclinicalvalidationofanovel4geneprognosticsignaturepredictingsurvivalincolorectalcancer |